Results 41 to 50 of about 59,410 (231)

Negotiating in a Foreign Land: Understanding the Curious Interactions Between Intracellular Mitochondria and Internalized Nanoparticles

Advanced Materials Interfaces, EarlyView.
Therapeutic nano‐drug delivery systems interact with cellular mitochondria in a multitude of ways. While the complexity of such interactions disrupts the mitochondrial electron transport chain and increases reactive oxygen species production, thereby contributing to nanoparticle toxicity, they also present unique theranostic opportunities in diseases ...
Sourav Bhattacharjee
wiley   +1 more source

Bullous fixed drug eruption due to erlotinib: A rare case report

Annals of Oncology Research and Therapy
Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various ...
Kallolinee Samal, Manoj Kumar Nayak, Srigopal Mohanty, Nibedita Dixit   +3 more
doaj   +1 more source

A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ‐SAFE Study

Arthritis &Rheumatology, EarlyView.
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez‐Giron, David Gazeley, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Evaluating a virtual paediatric adverse drug reaction clinic

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a common problem in paediatric health care. There is limited access to expertise in the evaluation and management of potential ADRs in children, limiting access to these services and creating delays in assessment and management.
Emily Hauck, Blanca Del Pozzo‐Magana, Michael Rieder   +2 more
wiley   +1 more source

Clinical Features and Drug Characteristics of Patients with Generalized Fixed Drug Eruption in the West of Iran (2005–2014)

Dermatology Research and Practice, 2015
Background. Generalized fixed drug eruption is a specific variant of fixed drug eruption with multifocal lesions. Diagnosis of this drug reaction is straightforward, but occasionally recognition of the causative drug is not possible. This study was aimed
Hossein Kavoussi, Mansour Rezaei, Katayoun Derakhshandeh, Alireza Moradi, Ali Ebrahimi, Harif Rashidian, Reza Kavoussi   +6 more
doaj   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Fixed Food Eruption Caused by Cashew Nut

Allergology International, 2008
Background: The diagnosis of fixed ‘drug’ eruption is not difficult for dermatologists, but it is difficult to identify the causative agent when the patient denies ingestion of any drugs. There have been some reported cases of fixed ‘food’ eruption. Case
Satoshi Fukushima, Masato Kidou, Hironobu Ihn   +2 more
doaj   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source

A case of entecavir-associated bullous fixed drug eruption and a review of literature

The Turkish Journal of Gastroenterology, 2019
Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the same site(s), generally observed following every intake of a causative drug. Delayed-type cellular hypersensitivity (Type IVC)
Selami Aykut Temiz, İlkay Özer, Arzu Ataseven, Sıddıka Fındık   +3 more
doaj   +1 more source

Generalized bullous fixed drug eruption successfully treated with cyclosporine

Dermatologic Therapy, 2020
Dear Editor, Fixed drug eruption (FDE) is a frequent adverse drug reaction (ADR), which may on rare occasions lead to a generalized bullous variant. This is characterized by the dissemination of erythematous-violaceous macules and plaques typical of FDE,
P. Vargas-Mora, S. García, F. Valenzuela, C. Morales   +3 more
semanticscholar   +1 more source